Related Experiment Video
Updated: May 27, 2026
10:18
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Endothelin-1 levels in chronic congestive heart failure
1Division of Cardiology, Kochi General Rehabilitation Hospital, Kochi City, Japan. m6537099@fc4.so-net.ne.jp
Wiener Klinische Wochenschrift
|November 25, 2011
Summary
Endothelin-1 levels correlate with human atrial natriuretic peptide (HANP) and brain natriuretic peptide (BNP) in chronic heart failure patients. This suggests endothelin-1 plays a key role in heart failure with preserved ejection fraction.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Background:
- Chronic congestive heart failure (CHF) involves complex neurohormonal dysregulation.
- Endothelin-1, human atrial natriuretic peptide (HANP), and brain natriuretic peptide (BNP) are implicated in cardiovascular disease.
- Understanding the interplay of these biomarkers is crucial for managing CHF severity.
Purpose of the Study:
- To evaluate endothelin-1 levels in patients with chronic congestive heart failure.
- To assess the relationship between endothelin-1 and cardiac dysfunction severity.
- To investigate the correlations between endothelin-1, HANP, and BNP.
Main Methods:
- Forty patients with chronic heart failure underwent echocardiography to determine left ventricular ejection fraction (EF).
- Serum levels of HANP, BNP, and endothelin-1 were measured.
- Exclusion criteria included acute myocardial infarction, unstable angina, and renal dysfunction.
Main Results:
- Endothelin-1 levels showed significant positive correlations with both HANP (r = 0.675, p < 0.0001) and BNP (r = 0.616, p < 0.0001).
- No significant correlation was found between endothelin-1 levels and left ventricular ejection fraction or end-diastolic volume.
- BNP levels showed a trend towards correlation with left ventricular ejection fraction (r = 0.315, p = 0.057).
Conclusions:
- Endothelin-1 interacts with HANP and BNP in the pathophysiology of chronic congestive heart failure.
- Endothelin-1 may play a significant role in chronic congestive heart failure, particularly in cases with preserved ejection fraction.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...